Literature DB >> 25727856

Natural history of idiopathic pulmonary fibrosis.

Hyun Joo Kim1, David Perlman2, Rade Tomic2.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a parenchymal lung disease characterized by progressive interstitial fibrosis. IPF has a poor prognosis, with a median survival time of 2-3 years from diagnosis, but varying from a few months to a decade. The natural history of IPF is highly variable and the course of disease in an individual patient is difficult to predict. Some patients with IPF experience rapid decline, others progress much more slowly, and some patients show periods of relative stability interspersed with acute deteriorations in respiratory function. Many clinical, radiographic, serologic, and histopathologic variables have been shown to predict mortality in IPF. However, the accuracy of these predictors varies due to the retrospective nature of some of the studies and variations in study design. The ability to identify clinical characteristics that predict disease progression and survival would be useful for counseling patients, treatment decision-making, and prompt consideration for lung transplantation. A number of indices for predicting mortality in patients with IPF are available, but they require further validation. As high-resolution computed tomography scans become more widely available and patients with IPF are diagnosed earlier, survival times following diagnosis will improve. Early referral to interstitial lung disease specialty centers is important for accurate diagnosis and may be associated with improved outcomes. The goal of this review is to examine the natural history of IPF, discuss predictors of mortality, and highlight the importance of prompt diagnosis and referral for patients with IPF.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acute exacerbations; Idiopathic pulmonary fibrosis; Natural history; Predictors of mortality; Progression

Mesh:

Year:  2015        PMID: 25727856     DOI: 10.1016/j.rmed.2015.02.002

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  41 in total

1.  The impact of idiopathic pulmonary fibrosis on health state utility values: evidence from Australia.

Authors:  E Haydn Walters; Andrew J Palmer; Ingrid A Cox; Barbara de Graaff; Hasnat Ahmed; Julie Campbell; Petr Otahal; Tamera J Corte; Ian Glaspole; Yuben Moodley; Nicole Goh; Sacha Macansh
Journal:  Qual Life Res       Date:  2021-05-17       Impact factor: 4.147

Review 2.  Nutritional status and muscle dysfunction in chronic respiratory diseases: stable phase versus acute exacerbations.

Authors:  Joaquim Gea; Antoni Sancho-Muñoz; Roberto Chalela
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

3.  Assessment of health-related quality of life in Australian patients with idiopathic pulmonary fibrosis: a comparison of the EQ-5D-5L and the AQoL-8D.

Authors:  Ingrid A Cox; Julie Campbell; Barbara de Graaff; Petr Otahal; Tamera J Corte; Yuben Moodley; Peter Hopkins; Sacha Macansh; E Haydn Walters; Andrew J Palmer
Journal:  Qual Life Res       Date:  2022-08-04       Impact factor: 3.440

4.  Neutrophil lymphocyte ratio as an indicator for disease progression in Idiopathic Pulmonary Fibrosis.

Authors:  Andrew Achaiah; Amila Rathnapala; Andrea Pereira; Harriet Bothwell; Kritica Dwivedi; Rosie Barker; Valentina Iotchkova; Rachel Benamore; Rachel K Hoyles; Ling-Pei Ho
Journal:  BMJ Open Respir Res       Date:  2022-06

5.  Second harmonic generation microscopy reveals altered collagen microstructure in usual interstitial pneumonia versus healthy lung.

Authors:  Robert Matthew Kottmann; Jesse Sharp; Kristina Owens; Peter Salzman; Guang-Qian Xiao; Richard P Phipps; Patricia J Sime; Edward B Brown; Seth W Perry
Journal:  Respir Res       Date:  2015-05-27

6.  Emodin Attenuates Bleomycin-Induced Pulmonary Fibrosis via Anti-Inflammatory and Anti-Oxidative Activities in Rats.

Authors:  Sheng-Lan Tian; Yang Yang; Xiao-Liu Liu; Qing-Bang Xu
Journal:  Med Sci Monit       Date:  2018-01-01

7.  The development of HEC-866 and its analogues for the treatment of idiopathic pulmonary fibrosis.

Authors:  Runfeng Lin; Zheng Zhang; Shengtian Cao; Wen Yang; Yinglin Zuo; Xinye Yang; Jiancun Zhang; Juan Xu; Jing Li; Xiaojun Wang
Journal:  RSC Med Chem       Date:  2021-06-02

8.  Six-SOMAmer Index Relating to Immune, Protease and Angiogenic Functions Predicts Progression in IPF.

Authors:  Shanna L Ashley; Meng Xia; Susan Murray; David N O'Dwyer; Ethan Grant; Eric S White; Kevin R Flaherty; Fernando J Martinez; Bethany B Moore
Journal:  PLoS One       Date:  2016-08-04       Impact factor: 3.240

9.  Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume.

Authors:  Martin Kolb; Luca Richeldi; Jürgen Behr; Toby M Maher; Wenbo Tang; Susanne Stowasser; Christoph Hallmann; Roland M du Bois
Journal:  Thorax       Date:  2016-09-26       Impact factor: 9.139

10.  Artesunate ameliorates lung fibrosis via inhibiting the Notch signaling pathway.

Authors:  Yujuan Liu; Guojin Huang; Biwen Mo; Changming Wang
Journal:  Exp Ther Med       Date:  2017-06-08       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.